Ads
related to: keytruda cancer drug- Side Effect Information
Learn More About Potential
Side Effects Here.
- Clinical Trials Results
Access Clinical Trial Results
and Information Here.
- Official Patient Website
Learn About a Treatment Plan
That May Be Right for You.
- Treatment Tips
Tips to Help You Before
and During Treatment.
- Financial Support
Find Information on Financial
Support Programs Here.
- Getting Started
Learn More About Possible Side
Effects When You Start Treatment.
- Side Effect Information
Search results
Pharma Stock Roundup: BAYRY's Q1 Earnings, JNJ's New Buyout, Pipeline Updates
Zacks via Yahoo Finance· 4 hours agoMerck MRK will discontinue the Keytruda plus vibostolimab co-formulation arm of a phase III melanoma...
Merck stopped a clinical trial for its experimental skin cancer drug after a high rate of side...
Quartz· 4 days agoThe study was testing whether a combination of the company’s flagship cancer drug Keytruda and its...
Merck stops testing combo drug for skin cancer as more patients discontinue
Reuters via Yahoo News· 4 days agoThis is the latest setback for the experimental drug, vibostolimab, and the related promising new...
Merck Halts Skin Cancer Drug Trial On High Discontinuation Rate - A Setback in High-Risk Melanoma...
Benzinga· 4 days agoThe trial evaluates the investigational coformulation of vibostolimab and Keytruda (pembrolizumab)...
Merck Ends Co-Formulation Arm of Keytruda High-Risk Melanoma Study
Morningstar· 4 days agoMerck & Co. has ended part of a late-stage study of a co-formulation of its blockbuster cancer drug Keytruda in certain skin-
Merck (MRK) Ends Keytruda Combo Melanoma Study Due to Futility
Zacks via Yahoo Finance· 3 days agoNumerous recent approvals and the expected launch of many additional indications, including in...
Merck halts research on combo drug for skin cancer
Becker’s Hospital Review· 5 days agoMerck will stop testing an experimental combination treatment for skin cancer patients in a late-stage study, the drugmaker said May 13. Merck was evaluating the use of the ...
Earnings call: AIM ImmunoTech highlights Q1 2024 progress on cancer trials
Investing.com· 2 days agoAIM ImmunoTech (NYSE: AIM ) Inc. (NYSE American: AIM) provided an optimistic update during its first...
Merck stops skin cancer combination therapy testing in late-stage study
Reuters· 4 days ago, opens new tab has discontinued testing a combination of an experimental antibody-based drug and...
3 Drug Stocks to Watch on Raised 2024 Earnings & Sales Guidance
Zacks via Yahoo Finance· 1 day agoHere we discuss three drugmakers, Eli Lilly and Company (LLY), Novo Nordisk (NVO) and Merck (MRK),...
Ads
related to: keytruda cancer drug
